Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.54 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MDH2 | P40926 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28056879 | 1.00 | MAOB (0.64) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| Hydrochloric Acid SCHEMBL9440598 | 0.98 | MAOB (0.62) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL588979 | 0.89 | MAOB (0.76) | MAOBNR4A2NR4A1NR4A3ALDH1A1 | |
| SCHEMBL9440593 | 0.88 | MAOB (0.61) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL10974452 | 0.88 | MAOB (0.61) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL3740175 | 0.88 | RAB9A (0.66) | MAOBMRGPRX4MEN1KMT2APLA2G4B | |
| SCHEMBL2328705 | 0.88 | MAOB (0.60) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL14315506 | 0.87 | SRD5A2 (0.60) | MAOBNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL17958912 | 0.87 | MAOB (0.59) | MAOBNR4A2NR4A1NR4A3MRGPRX4 | |
| SCHEMBL7881166 | 0.87 | MAOB (0.59) | MAOBNR4A2NR4A1NR4A3MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105518014-B | C-aryl glucoside derivative, preparation method and application thereof in medicine | 上海研健新药研发有限公司 | 2018-03-23 | — | — | CN | disclosed |
| CN-107311992-A | C aryl glucosides derivative, its preparation method and its in application pharmaceutically | 上海研健新药研发有限公司 | 2017-11-03 | — | — | CN | disclosed |
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8501771-B2 | Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-1987020-B1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-10-03 | — | — | EP | disclosed |
| EP-1987006-B1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090082391-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
| CN-101384583-A | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI AVENTIS (FR) | 2009-03-11 | — | — | CN | disclosed |
| US-6274735-B1 | RENIN INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-08-14 | — | — | US | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| WO-2000031067-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| EP-0979819-A1 | Process for the production of substituted 3-hydroxypiperidines | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-16 | — | — | EP | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-4910206-A | Endotoxin induced lung injury | SANDOZ PHARMACEUTICALS CORP. (US) | 1990-03-20 | — | — | US | disclosed |
| US-4029594-A | Novel liquid crystal compounds and electro-optic devices incorporating them | RCA CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082391-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, AHR, MCHR2 | MAOB 1131/4885NR4A2 2405/4885NR4A1 2229/4885 |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | MAOB 827/4885NR4A2 822/4885NR4A1 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.